A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma.
about
Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer.Bispecific antibodies engage T cells for antitumor immunotherapy.A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.Programmable self-assembly of antibody-oligonucleotide conjugates as small molecule and protein carriers.A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model.Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development.Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activityA dual-targeting triplebody mediates preferential redirected lysis of antigen double-positive over single-positive leukemic cells.Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors.Dual targeting strategies with bispecific antibodies.Immunogenicity of therapeutics: a matter of efficacy and safety.Diphtheria toxin-based targeted toxin therapy for brain tumors.Targeting a Cancer-Specific Epitope of the Epidermal Growth Factor Receptor in Triple-Negative Breast Cancer.Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR.Immunotoxin targeting CD133(+) breast carcinoma cells.Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer.Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors.
P2860
Q33907691-F7339EA4-5C11-4D32-A700-966FBC0571CEQ34009357-8331E96E-6B31-471D-AD2A-0177FAE3EC5AQ34174334-2A109602-A907-427C-9F48-A17F6AEE7FD7Q34993336-38335EE7-E1A4-4BFF-BA3B-8B0D5BCEB601Q35851889-CA3B057A-8649-4C34-82C1-6ADAC0CF1F9DQ35911544-9B170ABD-9776-4C8C-94AA-59FDBD4E042FQ36226862-0E3A9027-EFA1-4911-8A1F-BAD605848CCEQ37400550-BE8A5457-9994-444E-9F30-84AEE938EDCAQ37593702-BCCABAFB-9C58-46DC-8920-80506D0983F7Q37700709-1E2D6B4A-9975-4EC7-9A5C-0D072A5E7265Q37997559-6062C542-A0E2-4DB3-8199-4DA713D2A0BDQ38029120-476B58E9-76F6-4C6B-834E-B2CB2E00DF2AQ38108516-08EFB97C-4D5F-4DBA-99CC-64439EFDD1EEQ38778443-3046E63E-5004-4E49-BBC7-595736E7AE97Q38963363-8EBDE0A0-C233-460A-A8A6-6355283F42E4Q39173834-7F8D571F-04E9-48DF-BF0E-15650A290485Q39331689-B3D40BED-7767-4E3E-8223-A7A3BCF4987DQ51738705-17AA4DEA-F6EE-4F4A-8F04-6296B8E6415B
P2860
A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A novel reduced immunogenicity ...... f metastatic breast carcinoma.
@en
A novel reduced immunogenicity ...... f metastatic breast carcinoma.
@nl
type
label
A novel reduced immunogenicity ...... f metastatic breast carcinoma.
@en
A novel reduced immunogenicity ...... f metastatic breast carcinoma.
@nl
prefLabel
A novel reduced immunogenicity ...... f metastatic breast carcinoma.
@en
A novel reduced immunogenicity ...... f metastatic breast carcinoma.
@nl
P2093
P2860
P1476
A novel reduced immunogenicity ...... f metastatic breast carcinoma.
@en
P2093
Arkadiusz Z Dudek
Brad J Stish
Daniel A Vallera
Deepali Sachdev
Seunguk Oh
P2860
P304
P356
10.1158/1078-0432.CCR-09-0696
P407
P577
2009-09-29T00:00:00Z